Tohoku Univ. Technology：A Diagnostic Test Enabling Precision Oncology in Head and Neck Cancer：T25-030
Predicts Therapeutic Response to ICI and Anti-EGFR Antibody Treatments
For patients with platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), first-line therapy usually involves pembrolizumab (an immune checkpoint inhibitor; ICI) with chemotherapy (5-FU plus cisplatin/carboplatin), or pembrolizumab alone for PD-L1–positive cases defined by the combined positive score (CPS). As a second-line option, cetuximab (anti-EGFR antibody) plus paclitaxel (CET+PTX) is commonly used. Our study revealed that responses to pembrolizumab plus chemotherapy and subsequent CET+PTX are inversely associated in R/M-HNSCC, and that activation of the JAK–STAT pathway, particularly STAT3 phosphorylation, marks tumors resistant to pembrolizumab-based therapy but sensitive to CET+PTX. This diagnostic approach uses these biomarkers to guide treatment sequencing after ICI.
Inquire About This Product
basic information
please contact us or refer to the PDF for more details.
Price range
Delivery Time
Applications/Examples of results
please contact us or refer to the PDF for more details.
catalog（1）
Download All Catalogs
Company information
The revenue generated from technology transfer is reinvested into universities and researchers as new research funding, which is used to create further research outcomes. To ensure the smooth operation of this cycle, known as the "Intellectual Creation Cycle," we will actively promote technology transfer. The types of seeds we handle include patents, know-how, databases, and programs. We have established a collaborative framework by concluding basic technology transfer agreements with the following universities (as of April 1, 2026): - Tohoku University - Hirosaki University - Iwate University - Akita University - Fukushima University - Yamagata University - Tohoku Gakuin University - Iwate Medical University - Fukushima Medical University - Aizu University - Miyagi University - Hokkaido University - Muroran Institute of Technology - Showa Medical University - Asahikawa Medical University
![[Market Report] Global Market for Point-of-Care Diagnostic Tests](https://image.mono.ipros.com/public/product/image/123/2000940437/IPROS17678327490617014341.jpeg?w=280&h=280)
![[Research Material] Global Market for Lipid Metabolism Disease Treatment](https://image.mono.ipros.com/public/product/image/c46/2001467415/IPROS28734457935308214927.jpeg?w=280&h=280)
![Amenities Meter: Creating a Comfortable Working Space with IoT [Work Style Reform]](https://image.mono.ipros.com/public/product/image/6fb/2001027009/IPROS12754886358639934309.png?w=280&h=280)
